Compare TG Therapeutics Inc (TGTX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United States Natural Gas Fund — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while United States Natural Gas Fund trades at $11.01 (market cap $517.27M). The key difference: TG Therapeutics Inc is far larger — about 15.8× United States Natural Gas Fund's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and United States Natural Gas Fund for 22 Days on average.
| TGTX | UNG | |
|---|---|---|
Market Cap | $8.16B | $517.27M |
Volume | 1,735,121 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $59.06 | $16.90 |
52-Week Low | $26.94 | $9.63 |
Typical Hold Time | 16 Days | 22 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
UNG trades at $11.01, down 0.18% on the day, with a bullish technical signal from moving averages and neutral oscillators. The fund reported a net income of $65.15 million for 2024, though revenue was $0, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights record U.S. natural gas production and geopolitical tensions affecting energy markets.
The outlook for UNG is mixed, with bullish technicals and solid financials offset by exposure to volatile natural gas prices and high production levels. Investment opportunities lie in potential geopolitical supply disruptions, while risks include weather-dependent demand and sustained high output pressuring prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
